资源描述：
《抗HBV-DC治疗慢性HBV携带者的初步临床研究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、抗HBV-DC治疗慢性HBV携带者的初步临床研究［摘耍］冃的：观察HBsAg致皱患者口体外周血单个核细胞(PBMC)来源的树突状细胞(DC)疫苗(简称抗HBV-DC)治疗慢性HBV携带者的临床效果。方法：15例HBeAg阳性和5例HBeAg阴性的慢性HBV携带者接受临床试验。取外周静脉血25ml,用密度梯度离心及贴壁法获得单核细胞，以粒细胞-巨噬细胞集落刺激因子(GM-CSF)和白细胞介素4(IL-4)诱导扩增出DC,并予HBsA^致敏DC。笫7天收获DC静脉回输，1次/周，共4次。治疗前后检测IIBV标志物定量、HBV-DNA定量及肝功能。结果：治愈1例，好转18例，无效1例，
2、总有效率为95%(19/20),治愈率5%(l/20)o结论：抗HBV-DC静脉回输可有效地抑制慢性HBV携带者的病毒复制，降低并淸除病毒抗原，促进HBeAg/HBeAb的血清学转换，是一种安全、有效的治疗慢性HBV携带的方法。［关键词］树突状细胞：乙型肝炎病毒；疫苗；携带者［中图分类号］R456［文献标识码］A［文章编号11673-7210(2008)02(c)-055-03Clinicalresearchonthetreatmenteffectofanti~HBVdendriticcellonchronicHBVcarrierpatientsWUBang-ful,YANGJi
3、ang-yingl,ZHOUYun2,ZHANGDa~wei2,WENLingl,XIAOJian-kail,WANGQiao-yul,WUWei-hong1,ZHANGMei-hual,PANJiel,PENGYing-yu2,YANGJun2,WUYing2(1.GuangzhouMedicalCollegeAffiliatedTwelfthPeople'sHospitalofGuangzhouCity,Guangzhou510620,China;2.PubangBiologicalImmunologicTechnologyResearchCenterofGuangzhou,
4、Guangzhou510663,China)［Abstract］Objective:ToinvestigatethetreatmenteffectofautologousHBsAg-loadeddendriticcellsvaccine(anti-HBVDCs)onchronicHBVcarrierpatients.Methods:Monocyteswereisolatedfromperipheralbloodof20chronicHBVcarrierpatientsbyFicolbHypaquedensitygradientcentrifugatingandculturedwi
5、thplastic-adhereneemethod.DCswereinducedandproliferatedfromthemonocyteswithgranulocyte-macrophageclonystimulatingfactor(GM-CSF)andinterleukin-4(IL-4)for7days.AfterbeingincubatedwithHBsAg,DCswereinjoctedtopatients'veinfor4timesatoneweek'sinterval.HBVmarkers,HBV-DNAlevels,andliverfunctiontestsi
6、ntheserumofpatientsweretestedbeforeandaftertreatment.Results:Theeffectiveratewas95%(19/20),andthecureratewas5%(1/20)・TheHBsAglevelswere(226.05±97.85)ng/mland(86.47±79.33)ng/ml(t=6.28,P<0.001),theHBeAglevelswere(3.08±1.76)Ncu/mland(1.72±1.40)Ncu/ml(t=3.37,P=0.005),theHBeAblevelswere(0.19±0.44)
7、Ncu/mland(0.71±1.11)Ncu/ml(t=2.61,P=0.021),theHBV-DNAlevelswere(0.99±1.29)X108copy/mland(0.38±1.10)X108copy/ml(t=1.93,P二0.069),andtheALTlevelswere(25.42±8.44)U/Land(34.33±22.65)U/L(t=2・05,P二0.054)beforeandaftertreatment.TheHBeAg/HBeAbseroconv
